TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Reported revenues of $5.7 million in 4Q23, up 77% over prior year



Full year revenues of $18.5 million, up 49% over prior year



Gross Margin of 90% in 4Q23 and 86% for full year



CMS...

Related Keywords

Texas ,United States ,Mary Szela ,Intrahepatic Cholangiocarcinoma ,Trisalus Life Sciences ,Centers For Medicare Medicaid Services ,Linkedin ,Academic Oncology Centers ,University Of Texas Md Anderson Cancer Center ,Nasdaq ,Company Annual Report On Form ,Twitter ,Technology Healthcare Common Procedure Coding System ,Exchange Commission ,Trisalus Life Sciences Inc ,Society For Immunotherapy ,Current Medical Research ,Chief Executive Officer ,Trinav Infusion System ,Medicaid Services ,Trinav Infusion ,Ambulatory Payment Classification ,World Data Demonstrates Ability ,Successfully Treat Patients ,Higher Disease Burden ,Improve Delivery ,Pressure Enabled Drug Delivery ,Multiple Phase ,Uveal Melanoma Liver Metastases ,Hepatocellular Cancer ,Leading Academic Oncology Centers Across ,Determine Which Indication ,Full Data Set Will ,Second Half ,Cancer Center ,Novel Pancreatic Infusion ,Pancreatic Infusion System ,Trinav Large ,Financial Results ,Full Year ,Late Filing ,Annual Report ,Infusion System ,Pancreatic Retrograde Venous Infusion System ,Pressure Enabled Regional Immuno Oncology ,Private Securities Litigation Reform Act ,Balance Sheets ,Stockholder Equity ,